HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.04 USD
-0.16 (-0.20%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $79.01 -0.03 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
HealthEquity (HQY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$97.93 | $110.00 | $87.00 | 23.65% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for HealthEquity comes to $97.93. The forecasts range from a low of $87.00 to a high of $110.00. The average price target represents an increase of 23.65% from the last closing price of $79.20.
Analyst Price Targets (14)
Broker Rating
HealthEquity currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.15 a month ago based on 13 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 84.62%, while Buy represented 15.38%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 11 | 11 | 11 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.15 | 1.15 | 1.15 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | JMP Securities | Constantine Kyriakos Davides | Not Available | Strong Buy |
3/22/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
3/22/2024 | Barrington Research | Alexander P Paris | Strong Buy | Strong Buy |
2/27/2024 | BTIG | David M Larsen | Strong Buy | Strong Buy |
12/14/2023 | Raymond James | Charles G Peters | Moderate Buy | Moderate Buy |
9/21/2023 | Robert W. Baird & Co. | Mark S Marcon | Hold | Strong Buy |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $97.93 |
LT Growth Rate | 29.00% |
Industry | Medical Services |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | 0.66 |